Immunology Flashcards

1
Q

Two types of immune responses

A

Innate
- components already at location of infection, and respond immediately with a generalised response.
Adaptive/specific
- T and B cells located away from the infection.
- When respond they do so in a specialised way to specifically target the pathogen
- takes longer
Complement system works alongside these two responses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Initial immune response

A
  1. Macrophages recognise pathogen and activate the immune system.
  2. Dendritic cells pick up antigens from pathogen and travel through the blood and lymphatic system to locate the specific T and B cells and activate them.
  3. Invading pathogen activates the complement system through the lectin and alternative pathways.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Innate immune system - macrophage actions

A
  1. Macrophages recognise pathogens through pathogen associated molecular patterns (PAMPs) on their surface. Through phagocytosis they recognise and detroy pathogens.
  2. If the pathogen assault is too great for this to work alone, macrophages release cytokines (signalling proteins - which triggers a localised inflammatory immune response).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Innate immune system - cytokines

A

signalling proteins - which triggers a localised inflammatory immune response.
Cytokines recruit and activate more cells of the innate immune system - macrophages, monocytes (precursors to macrophages) and neutrophils (another phagocyte).
The inflammatory process driven by cytokines causes vasodilation, increased vascular permeability, mast cell degradation, clotting system activation and kinin system activation. Cytokines release interleukins as part of this inflammatory response.
This process of localised inflammation is called the acute phase reaction.
This leads to systemic inflammation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Acute phase response

A

Process of localised inflammation from cytokine activation and interleukin production causing a systemic inflammatory response.
IL-1 release - acts on brain to cause fever, decreased appetite and lethargy
IL-6 release - acts on liver to release acute phase proteins (opsonins - eg CRP)
IL-8 release - recruits and activates neutrophils
IL-2 and IL-12 - activate natural killer cells.
TNF-alpha does all the above by itself.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Complement system

A

Complement proteins C1-C9
Proteins activate each other in the complement cascade.
These work by activating opsonins, causing inflammation and destroying pathogens.
The complement system is activated either directly by the pathogens (lectin and alternative pathways activate) or through antibody-antigen complexes (classical pathway).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Adaptive/specific immune system.

A

B and T cells are lymphocytes which make up the adaptive immune system.
Found in the lymphatic system, sequestered in lymph nodes waiting for invading pathogens.
Dendritic cells travel from the site of the pathogens infection carrying antigens and display them on their cell surface on HLA class II molecules. This is then presented to the T and B cells until the correct ones are found and activated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

T cells

A

Every pathogen has antigens unique to them they express on their surface.
Each T cell has T cell receptor on it’s surface specific to a single antigen.
CD4 T cells are activated by the dendritic cells presenting the correct antigen on the HLA class II molecules.
CD4 T cells then proliferative and become T helper cells. These present the antigen on their HLA class 1 molecule which is recognised by CD8 T cells.
The T helper cells also release cytokines which cause the CD* cells to proliferative and turn into cytotoxic T cells.
Cytotoxic T cells kills cells that have been infection by pathogens (i.e. virally infected cells).
The T helper cells also travel to the the site of the infection and release cytokines to stimulate the innate immune system further.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

B cells

A

Every pathogen has antigens unique to them they express on their surface.
Each B cells has antibodies on it’s surface specific to a single antigen.
T helper cells release cytokines that activate B cells and turn them into plasma cells - these make antibodies and Memory B cells which form the immune memory for future infections.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Antibodies

A

Produced by plasma cells (differentiated B cells) - part of adaptive immune system.
Y shaped protein- variable region which matches different antigens, other end is fixed in shape and can be recognised by various cells in the immune system.
1. Attach to enemy toxins (antigens) and neutralise their effect
2. Attach to the antigen receptors on pathogens and prevent them from carrying out their function (can prevent the viral invasion)
3. Attach themselves to pathogens and cause aggultination which slows their spread down
4. Can act as opsonins to the pathogen and help the macrophages and neutrophils to recognise and phagocytose them.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are natural killer cells, including different subsets which are relevant to reproductive medicine. What is their normal function.

A

Lymphoid progenitor cell.
Part of the innate immune system.
Have uterine and peripheral subsets.
Uterine - CD56birght, CD16-ve, high KIR, low cytotoxicity,
Peripheral - CD56dim, CD16+ve, low KIR, high cytotoxicity,
Peripheral NK involved in cell death - namely viruses and cancer cells. Don’t require APC priming or MHC presentation. Release perforin and granzymes, secrete cytokines.
uNK - involved in implantation, vascular remodelling and trophoblastic invasion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How are NK cells tested and reported

A

pNK - blood test - flow cytometry
uNK - endometrial biopsy - immunofluorence, or flow cytometry.
- varies widely during menstrual cycle, usually taken in the luteal phase, can be reported as number or percentage of circulating lymphocytes or total stromal endometrial cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Theories behind NK cells and infertility

A
  • increased uNK levels may cause increased production of angiogenic factors leading to increased peri-implantation blood flow and excessive oxidative stress to trophoblast cells.
  • Other evidence suggests that uNK have a predisposition to secrete pro-inflammatory cytokines akin to Th1-type cytokines while dampening anti-inflammatory Th2-type cytokines that are necessary to maintain healthy pregnancy.
  • Different combinations of parental HLA-C and maternal KIR allotypes on livebirth outcome in women undergoing ART has highlighted that inadequate, rather than excessive, activation of uNK may be the cause of RPL and RIF.

uNK very important in spiral artery remodelling alongside macrophages

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

uNK KIR and HLA

A

KIR (Killer-cell immunoglobulin like receptors) are receptors found on NK cells.
HLA-C is the only MHC1 complex presented on extra-villous trophoblast.

It has been postulated that an adequate interaction between maternal KIRs and their ligands, the HLA class I molecules, expressed by the extravillous trophoblast cells is crucial for sustained implantation.

By binding to HLA-C KIRs either promote or inhibit NK cell activity.
An increased risk of RIF is observed in women carrying the HLA-C2 allotype and the HLA-G allele with a 14 bp insertion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Possible immune therapies listed in ESHRE RPL guideline and recommendation

A

Lymphocyte immunisation therapy - should not be used as it has no significant effect and there may be serious adverse effects (++– strong).
Intravenous immunoglobulin (IVIG) - repeated and high dose IVIG very early in pregnancy may improve LBR in women with 4 or more unexplained RPL (++– conditional)
Prednisolone - not recommended as a treatment (++–strong)
Anticoagulants - heparin and LDA are not recommended, they don’t improve LBR. (+++- strong)
Intralipid therapy - Insufficient evidence to recommend intralipid therapy for improving LBR (+— strong).
G-CSF - No evidence to recommend G-CSF (+++- strong)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Possible immune therapies listed in ESHRE RIF guideline and recommendation

A

Intential endometrial injury (not recommended)
G-CSF - administration either intrauterine or subcut is not recommended
Intravenous intralipid infusion - not recommended
IVIG - not recommended
Intrauterine autologous PBMC infusion - not recommended
Intrauterine PRP infusion - not recommended
Intrauterine hCG infusion - not recommeded
LMWH - not recommended

17
Q

Lymphoctye immunisation therpay - RPL

A

Immunised with partner lymphocytes (or with a third party donor).
Cochrane review of 12RCTs found no benefit in LBR in patients with RPL.
Concerns over risk of neonatal alloimmune thrombocytopenia, and transfer of infections and ?long term malignancy risk increased.

should not be used as it has no significant effect and there may be serious adverse effects (++– strong).

18
Q

IVIG - RPL and RIF

A

Known to reduce symptoms in many autoimmune and inflammatory diseases (interferes with antigen presenting cells, neutralisation of inflammatory cytokines, down regulates B and T cell function

RPL -
1 RCT showing benefit in LBR if given for 5 days at high dose in 4th week of pregnancy, in women with 4 or more unexplained RPL.
Also signficiant increase is SGA/fetal growth restriction and preterm birth after IVIG. 4 congenital anomalies vs 1 in the placebo - non-significant.
“ repeated and high dose IVIG very early in pregnancy may improve LBR in women with 4 or more unexplained RPL (++– conditional)”
Meta-analysis done beofre this study shows no benefit to use.

RIF -
Some benefits seen in cohoty/cross-sectinal stufies with LBR but RCTs lacking so not recommended.

Side effects of headache are common.

19
Q

prednisolone

A

RPL
The evidence points toward some beneficial effect of prednisolone in women with RPL selected due to positivity for selected biomarkers. However, based on adverse events associated with the use of prednisone, the GDG decided to recommend against treatment awaiting further studies.
2014 RCT 150 with RPL, increased LBR in the prednisolone group.

20
Q

Aspirin and Heparin

A

RPL (Not recommended strong +++-)
2014 Cochrane review - based on this cochrane meta-analysis and results of two subsequent large randomized controlled trials there is no
evidence that heparin alone, aspirin alone, or heparin in combination with low-dose aspirin improves the live birth rate in unexplained RPL.

RIF (not recommended)
A meta-analysis investigated the use of LMWH in patients with RIF (3 failed ET) but failed to show an effect of LMWH on LBR (RR 1.38; 95% CI 0.64–2.96; 2 RCTs; n¼71) and CPR (RR1.39; 95% CI 0.87–2.23; 2 RCTs; n¼218) (Busnelli et al., 2021).
The included studies had small study populations including a mix of patients with RIF, some with thrombophilia and some who were not tested or negative for thrombophilia

21
Q

Intralipid

A

Intravenous lipid emulsion. Intravenous intralipid infusion has been proposed to have a role in immune modulation through the reduction of platelet aggregation, a decrease of IL-2, tumour necrosis factor-a, and IL-1b production as well as suppression of NK cell levels and activity.

RPL (not recommended strong +—)
No randomized controlled trial has so far tested Intralipid versus no treatment or placebo. One RCT compared to IVIG and was the same outcomes.

RIF (not recommended)
A systematic review and meta-analysis reported a higher CPR and LBR but concluded there is limited evidence to support the use of intravenous intralipid at the time of ET in women with a history of RIF. (Rimmer et al, 2021) - A retraction watch review has authors with other retracted papers in 2 of 5 studies

22
Q

G-CSF

A

Granulocyte colony stimulating factor is a growth factor that plays a role in embryo implantation, and continuation of pregnancy. It temporarily suppresses the immune response, recruits dendritic cells, promotes Th@ cytokine secretion, activating Tregs, vascular remodelling.

RPL (No recommended strong _+++)
A high-quality multicentre RCT (RESPONSE) included 150 patients with RPL who were randomized to recombinant G-CSF or placebo (Eapen et al., 2019). The live birth rate was 59.2% in the G-CSF group and 64.9% in the placebo group (RR 0.9; 95%CI 0.7-1.2) suggesting no beneficial effect of G-CSF in unexplained RPL.

RIF (not recommended)
Might improve CPR but not LBR in meta-analysis x2

23
Q

Intrauterine autologous PBMC

A

peripheral blood mononuclear cell infusion
Local production of cytokines by PBMC which might improve trophoblastic invasion.

RIF (not recommended)
In all studies and RCTs, the study populations are small and the definitions for RIF are inconsistent. Furthermore, techniques to prepare PBMCs differed substantially between studies (co-cultured in the presence of hCG, corticotrophin-releasing hormone, HMG, a mixture of fresh and co-cultured PBMCs). Safety profile not available.
Meta-analysis and RCT did indicate improvement in LBR.

24
Q

Intrauterine hCG injection

A

hCG infusion may help to initiate and control blastocyst invasion and improve immune tolerance from the mother.

RIF (not recommended)
Evidence is suggestive of benefit but mainly derived from small and uncontrolled studies rather than RCTs. The one RCTs is from authors with multiple other retracted papers.

25
Q

Platelet rich plasma (intrauterine infusion)

A

Autologou concentrate of platelets in plasma. Cytokines and growth factors are thought to exert a regenerative effect on tissues and cells.
Some studies showing benefit - RCT out of Iran improvement in LBR, but ESHRE deemed not sufficient to support the use of PRP

26
Q

Describe the components which contribute to maternal tolerance to a fetus

A
  • Immune changes favour trophoblast invasion
  • Shift to Th2 response (lower Th1:Th2 ratio)
    o Th2 cytokines: IL-4, 5, 9, 10, 13
  • Uterine NK cells increase
    o Stimulate growth and trophoblast and invasion
    o Secrete cytokines: G-CSF, M-CSF, GM-CSF; LIF
  • Monocytes and macrophages increase in decidua
    o Remove debris associated with trophoblast invasion
  • Immune mechanisms allow for trophoblast to escape maternal immune attack
  • Trophoblasts do not express MHC 1a antigens (HLA-A, HLA-B)  hence not recognized as foreign by maternal T cells
  • Trophoblasts do express MHC 1b antigens (HLA-G, HLA-E)  bind inhibitory receptors on uNK cells  prevent lysis of trophoblast by uNK cells
27
Q
A